Calliditas Therapeutics AB (CALT)
20.13
+0.13
(+0.65%)
USD |
NASDAQ |
May 06, 16:00
19.56
-0.57
(-2.83%)
After-Hours: 20:00
Calliditas Therapeutics Debt to Equity Ratio: 2.806 for Dec. 31, 2023
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| December 31, 2023 | 2.806 |
| September 30, 2023 | 2.102 |
| June 30, 2023 | 1.505 |
| December 31, 2022 | 0.9305 |
| September 30, 2022 | 0.6173 |
| June 30, 2022 | 0.6066 |
| March 31, 2022 | 0.2211 |
| December 31, 2021 | 0.1876 |
| September 30, 2021 | 0.1485 |
| Date | Value |
|---|---|
| June 30, 2021 | 0.00 |
| March 31, 2021 | 0.00 |
| December 31, 2020 | 0.00 |
| September 30, 2020 | 0.00 |
| June 30, 2020 | 0.00 |
| March 31, 2020 | 0.00 |
| December 31, 2019 | 0.00 |
| September 30, 2019 | 0.00 |
| June 30, 2019 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
Jun 2019
2.806
Maximum
Dec 2023
0.5069
Average
0.0742
Median
Debt to Equity Ratio Benchmarks
| DBV Technologies SA | -- |
| Cellectis SA | 0.3968 |
| Adaptimmune Therapeutics PLC | 0.00 |
| Akari Therapeutics PLC | -- |
| Biodexa Pharmaceuticals Plc | 0.00 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 184.69M |
| Total Liabilities (Quarterly) | 151.43M |
| Shareholders Equity (Quarterly) | 33.26M |
| Current Ratio | 3.132 |
| Net Debt Paydown Yield | -1.46% |